This study aims to evaluate the pharmacokinetic/pharmacodynamic drug-drug interactions between DWP16001, DWC202407, and DWC202408 in healthy adults
This study aims to evaluate the pharmacokinetic interactions, pharmacodynamic interactions, safety, and tolerability of DWP16001, DWC202407, and DWC202408 in healthy adults
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
34
1 tablet, Orally, Once daily single dose
1 tablet, Orally, Twice daily
1 tablet, Orally, Once daily single dose
Seoul National University Hospital
Seoul, South Korea
Cmax,ss of DWP16001
Peak Plasma Concentration at steady-state
Time frame: 0-24 hours
AUCtau,ss of DWP16001
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: 0-24 hours
Cmax,ss of DWC202407
Peak Plasma Concentration at steady-state
Time frame: 0-12 hours
AUCtau,ss of DWC202407
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: 0-12 hours
Cmax,ss of DWC202408
Peak Plasma Concentration at steady-state
Time frame: 0-24 hours
AUCtau,ss of DWC202408
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: 0-24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.